<DOC>
	<DOCNO>NCT00034658</DOCNO>
	<brief_summary>This study design evaluate safety , tolerance efficacy Posaconazole ( SCH 56592 ) open label , treatment protocol subject invasive fungal infection : A : refractory resistant standard antifungal therapy ; B : currently effective therapy ; C : prior history serious , severe life-threatening toxicity receive antifungal therapy ; D : pre-existing organ dysfunction precludes administration standard antifungal therapy .</brief_summary>
	<brief_title>Open Label Study Posaconazole Treatment Invasive Fungal Infections ( Study P00041 )</brief_title>
	<detailed_description>The current clinical trial design provide posaconazole ( SCH 56592 ) subject invasive fungal infection ) refractory resistant standard antifungal therapy b ) currently effective therapy . Subjects invasive fungal infection enrol control , randomize clinical trial . Secondly , clinical trial also design provide posaconazole ( SCH 56592 ) subject invasive fungal infection c ) experience serious severe toxicity receive standard antifungal therapy ) pre-existing organ dysfunction renal dysfunction require standard antifungal therapy preclude toxicity associate therapy . This clinical trial also serve allow collection preliminary data regard safety efficacy posaconazole ( SCH 56592 ) variety invasive fungal infection although serious life-threatening sufficiently rare study control , randomize clinical trial .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Inclusion Criteria Proven probable invasive fungal infection accord EORTC/MSG criterion . IFI document refractory standard antifungal therapy OR intolerant standard therapy . Able take oral medication take medication via enteral feed tube . Exclusion Criteria Concurrent progressive neurological disease ( except due invasive fungal infection ) Use medication know interact azoles may lead lifethreatening side effect . Prior enrollment study . Subjects life expectancy le 72 hour .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Aspergillosis , Candidiasis , Cryptococcosis ,</keyword>
</DOC>